Gating Mechanism for Biased Agonism at Angiotensin II Type 1 Receptors
Molecules · 30.05.2025 · 30 (11) · 2399
DOI: 10.3390/molecules30112399 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 30.05.2025. Verfasst von Graham J Moore und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pepmetics Inc., 772 Murphy Place, Victoria, BC V6Y 3H4, Canada. Hauptthemen laut MEDLINE: Angiotensin II, Receptor, Angiotensin, Type 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
For the interaction of angiotensin II (AngII) with AngII type 1 receptors (AT1R), two potential proton hopping pathways have been identified, each associated with distinct physiological outcomes. The octapeptide AngII (Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8) appears to form a charge relay system (CRS) in solution in which the C-terminal carboxylate abstracts a proton from the His6 imidazole group, which, in turn, abstracts a proton from the Tyr4 hydroxyl (OH) group, creating a tyrosinate anion. When AngII binds to the AT1R, the CRS can be reconstituted with D281 of the receptor taking up the role of the Phe8 carboxylate in the tripartite interaction, whilst the Phe8 carboxylate forms a salt bridge with K199 of the receptor. As a consequence, the Tyr4 OH of AngII is positioned with accessibility to either the Phe8 carboxylate (bound to K199) or the His6 imidazole (activated by D281), thereby creating a potential gating mechanism for AT1R receptor signaling. This study summarizes evidence based on structure activity data for various analogs wherein Tyr4 OH interaction with His6 imidazole (CRS formation) leads to G protein sequestration and vasoconstriction, whereas Tyr4 OH interaction with Phe8 carboxylate (bound to K199) engenders arrestin-mediated vasodilation and receptor desensitization. These findings, combined with quantum mechanical (semiempirical) calculations of CRS proton transfer presented herein, provide insights for the therapeutic targeting of angiotensin receptor blockers (sartans) and the development of second-generation drugs (bisartans).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pepmetics Inc., 772 Murphy Place, Victoria, BC V6Y 3H4, Canada.
- THERAmolecular, LLC, Rodeo, NM 88056, USA.
- Institute for Sustainable Industries and Liveable Cities, Victoria University, Melbourne, VIC 8001, Australia.
- Institute for Health and Sport, Immunology and Translational Research Group, Victoria University, Werribee, VIC 3030, Australia.
- School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC 3000, Australia.
- School of Health Sciences, The University of Notre Dame Australia, Sydney, NSW 2008, Australia.
ORCID-Profile: Laura Kate Gadanec, Vasso Apostolopoulos, John M Matsoukas
Zitieren
APA
Moore, G. J., Ridgway, H., Gadanec, L. K., Apostolopoulos, V., Zulli, A., & Matsoukas, J. M. (2025). Gating Mechanism for Biased Agonism at Angiotensin II Type 1 Receptors. Molecules, 30(11), 2399. https://doi.org/10.3390/molecules30112399
Vancouver
Moore GJ, Ridgway H, Gadanec LK, Apostolopoulos V, Zulli A, Matsoukas JM. Gating Mechanism for Biased Agonism at Angiotensin II Type 1 Receptors. Molecules. 2025;30(11):2399. doi:10.3390/molecules30112399
BibTeX
@article{Moore2025,
author = {Moore, Graham J and Ridgway, Harry and Gadanec, Laura Kate and Apostolopoulos, Vasso and Zulli, Anthony and Matsoukas, John M},
title = {Gating Mechanism for Biased Agonism at Angiotensin II Type 1 Receptors},
journal = {Molecules},
year = {2025},
volume = {30},
number = {11},
pages = {2399},
doi = {10.3390/molecules30112399}
}
EUVIMED